CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), today announced the launch of Expression of Hope III, a global program of inspiration and awareness featuring works of art by the community of people affected by lysosomal storage disorders (LSD). This unique program encourages anyone affected by an LSD to create and submit a work of art that expresses their experiences of living with a rare, inherited disease. Through the Expression of Hope program, Genzyme furthers its long-standing history of collaboration with patient advocacy organizations around the world to help raise awareness and build a stronger global network of support for people affected by LSDs.
“Being diagnosed with a lysosomal storage disorder often creates a sense of isolation for patients and families,” said Jamie Ring, Genzyme’s vice president of global patient advocacy and humanitarian programs, adding, “Through Expression of Hope, anyone whose life has been touched by an LSD – including caregivers, family members, and friends – is invited to use the power of art to share their unique story with the world. Our goal is to use works of art to help more people learn about the impact of LSDs and join the effort to support people affected by them.”
The Expression of Hope program will be accepting submissions through December 5, 2014. Submitted artwork that meets program guidelines will be exhibited in the online gallery on the Expression of Hope web site (www.expressionofhope.com). Select works of art will also be featured in art exhibitions and program materials beginning in 2015.
Through Expression of Hope, anyone who has been touched by an LSD can submit an original work of art on paper or canvas, such as a painting, photograph or sketch. Artists of all ages and artistic ability, including family members, friends and healthcare workers, can participate. Once an artist has completed a piece, it should be photographed and digitally submitted to the Expression of Hope website. All submitted works that meet entry criteria will be presented on the Expression of Hope website. When the submission period closes on December 5, 2014, a panel of art experts will then identify submissions to be designated as Featured Art, which will be displayed in global exhibits and materials. LSD patient organizations around the world are invited to participate in Expression of Hope by promoting the program in their communities. To learn more about Expression of Hope or to submit a work of art, visit www.expressionofhope.com.
Lysosomal storage disorders, also known as lipid storage disorders, are a group of inherited metabolic conditions in which fatty materials (lipids) accumulate in various cells and tissues in the body. People with these disorders either do not produce enough of an enzyme required to break down (metabolize) lipids, or they produce enzymes that do not work properly. Over time, the build-up of lipids can lead to cellular and tissue damage, particularly in the brain, peripheral nervous system, liver, spleen, and bone marrow.1 Examples of LSDs include Gaucher disease and Fabry disease.
About Expression of Hope
Expression of Hope is a global program of inspiration and awareness featuring works of art by the lysosomal storage disorder community. In collaboration with LSD patient organizations around the world, Genzyme launched the Expression of Hope program in 2006 to give those impacted by lysosomal storage disorders (LSDs) the opportunity to raise awareness of these rare genetic diseases. More than 100 patients and caregivers expressed their unique stories through their original pieces of artwork. Building on that initial success, Genzyme launched the second Expression of Hope program in 2009, and once again the global community responded with enthusiasm, creativity and insight. The third Expression of Hope program further reinforces the commitment of individuals affected by lysosomal storage disorders to building awareness and expressing their unique stories through art.
About Genzyme, a Sanofi Company
Genzyme has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years. We accomplish our goals through world-class research and with the compassion and commitment of our employees. With a focus on rare diseases and multiple sclerosis, we are dedicated to making a positive impact on the lives of the patients and families we serve. That goal guides and inspires us every day. Genzyme’s portfolio of transformative therapies, which are marketed in countries around the world, represents groundbreaking and life-saving advances in medicine. As a Sanofi company, Genzyme benefits from the reach and resources of one of the world’s largest pharmaceutical companies, with a shared commitment to improving the lives of patients. Learn more at www.genzyme.com.
Genzyme® is a registered trademark of Genzyme Corporation. All rights reserved.
Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
Forward Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group’s ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2013. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.
1 National Institutes of Health, Lipid Storage Diseases Fact Sheet